Sawhney Roger reported option exercise involving 52,533 derivative units of Arbutus Biopharma Corp at $0.00 for $0 on Sep 18, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Sep 23, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
52,533Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
105,067Direct
Trade date
Sep 18, 2026Option exercise
Filed
Sep 23, 2026, 8:31 PM ET6-day reporting delay
Accession
0001447028-26-000051Code M · Transaction 228755
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Option exercise52,533$3.34$175,460.22Trade 228752
Sep 18, 2026Option exercise78,800$4.24$334,112Trade 228753
Sep 18, 2026Tax withholding100,508$5.07−$509,575.56Trade 228754
Sep 18, 2026Option exercise78,800$0.00$0Trade 228756
5 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 6 calendar days after the transaction date.

ABUS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ABUS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 1, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. F2: The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the August 4, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date. F3: The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date.